Renal Anemia Clinical Trial
Official title:
Different Doses of Roxadustat Treatment on Hemoglobin Target-met in Peritoneal Dialysis Patients
A multi-center, randomized, controlled study to evaluate the effect of different doses of roxadustate on hemoglobin target-met in peritoneal dialysis patients
Roxadustat is an orally hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to promote erythropoiesis on patients with chronic kidney disease. Two phase 3 clinical trials have verified the efficacy and safety of roxadustate as therapy for anemia in patients with CKD and undergoing dialysis. A high increasing rate of Hb or Hb overshooting triggered by roxadustat need dosing reduction or even drug withdrawal, possibly leading to a large Hb variation and adverse subsequences. Therefore, we were of interest to investigate whether a lower starting dose of roxadustat could achieve comparable Hb target at week 12 while lowering the risk for Hb over 130g/L through a prospective peritoneal dialysis (PD) cohort. Peritoneal dialysis patients diagnosed with renal anemia will be divided into standard roxadustat dosage group and lower roxadustat dosage group. After 12 weeks, we will compare the target-met, overshooting and variation ratio of hemoglobin between these two groups. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04925661 -
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
|
Phase 1 | |
Active, not recruiting |
NCT03388385 -
Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD
|
Phase 4 | |
Completed |
NCT05035641 -
A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
|
Phase 2 | |
Completed |
NCT02299661 -
Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease
|
Phase 1 | |
Active, not recruiting |
NCT05265325 -
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
|
Phase 2 | |
Completed |
NCT05864261 -
Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers
|
Phase 4 | |
Active, not recruiting |
NCT05085275 -
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02708914 -
Study to Compare the Safety and Efficacy of UB-851 and Eprex®
|
Phase 3 | |
Completed |
NCT02041208 -
Variability of Hemoglobin Levels After Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT04775615 -
Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects.
|
Phase 1 | |
Completed |
NCT00298441 -
Efficacy of Intravenous Iron Administration in Hemodialysis Patients
|
Phase 4 | |
Active, not recruiting |
NCT04408820 -
Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
|
||
Completed |
NCT01543477 -
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia
|
||
Completed |
NCT05951192 -
A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
|
Phase 4 | |
Recruiting |
NCT04360902 -
Assessment of an Anemia Model Predictive Controller for Anemia Management in Hemodialysis Patients
|
N/A | |
Not yet recruiting |
NCT03480178 -
Renal Anemia Refractory to Erythropoietin
|
||
Completed |
NCT01306409 -
Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)
|
Phase 4 | |
Completed |
NCT00322413 -
Comparison of Epoetin Alfa and Epoetin Omega in Anemic Dialysis Patients:Results of Efficacy Trial
|
Phase 3 | |
Recruiting |
NCT05970172 -
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02947438 -
Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)
|
Phase 3 |